EuroBiotech—More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Lundbeck offloaded two preclinical programs to AstraZeneca. The deal continues Lundbeck’s push to shed assets that are outside of its area of focus. Statement

> UniQure presented data on its hemophilia B gene therapy program. The data suggest the vector used by uniQure achieves liver transduction in the presence of pre-existing anti-AAV5 neutralizing antibodies. Release 

> 4D Pharma gained clearance to trial a commensal bacteria strain in cancer patients. The trial will look at the immunomodulatory effects of MRx0518 in people with solid tumors. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sensorion raised €8.7 million ($10.2 million). The money will fund the completion of a phase 2 trial of SENS-111 in patients with rare ear disease vestibular neuritis. Release 

> Cellectis gained clearance to increase the dose levels in a phase 1 trial of off-the-shelf CAR-T drug UCART123. The French biotech is also opening another site in a bid to increase the speed of enrollment. Statement 

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.